Antibe Therapeutics Announces Administrative Items and Congratulates Dr. John Wallace on Publication in Nature Reviews
05 Maio 2015 - 8:45AM
Business Wire
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV:ATE)
announced today the following:
Antibe wishes to congratulate its CSO, Dr. John Wallace, on the
publication of a paper entitled “Hydrogen sulfide-based
therapeutics: exploiting a unique but ubiquitous gasotransmitter”
in the prestigious journal, Nature Reviews Drug Discovery. The
paper, co-authored by Dr. Wallace and Dr. Rui Wang, written in the
fall of 2014, will appear in the journal’s May 2015 edition. A copy
of the paper is available on the Company’s website.
Antibe is pleased to announce that it has become eligible for
the book-entry delivery and depository services of The Depository
Trust Company (the "DTC") to facilitate electronic settlement and
transfer of its common shares in the US. Securities approved for
electronic clearance and settlement through the DTC are considered
"DTC eligible." DTC eligibility enables Antibe’s stock to be traded
by a wider selection of US brokerage firms, many of whom require
DTC eligibility as a prerequisite for trading.
The Company announced that it has granted a previous officer
148,936 common shares in the Company at the April 30, 2015 closing
market price of $0.235 per common share for a total value of
$35,000. This grant has been made in exchange for the officer
waiving a portion of the cash component of the officer’s
severance.
Finally, Antibe announced that it has granted options to Hamza
Thindal Capital Corporation (“HTCC”) in exchange for consulting
services to be provided by HTCC under the terms of a consulting
agreement. Under the terms of the agreement, HTCC will be granted
300,000 options. Such options will vest quarterly starting on the
date of the grant, will be exercisable at a price of $0.235, and
will expire May 5, 2018
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation.
Antibe’s technology involves linking a hydrogen sulfide-releasing
molecule to an existing drug to produce a patented, improved
medicine. Antibe’s lead drug ATB-346 targets the global need for a
safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain
and inflammation. ATB-352, the second drug in Antibe’s pipeline,
targets the urgent global need for a safer analgesic for severe
acute pain.
www.antibethera.com
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Important Note on Forward Looking Statements
Antibe Therapeutics Inc.Dan Legault, 416-473 4095Chief Executive
Officerdan.legault@antibethera.com
Antibe Therapeutics (TSXV:ATE)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Antibe Therapeutics (TSXV:ATE)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025